2026 Q2 Portfolio Activity
In 2026 Q2, Birchview Capital, LP maintained a portfolio of 87 distinct positions. The most significant new addition was ABIVAX SA, now representing 1.06% of the total fund value. They heavily accumulated shares in KLA CORPORATION, increasing the position by 797.6%. The fund also reduced its exposure to STRUCTURE THERAPEUTICS INC by 76.0%.
Position History
hover any row below to update
Loading…
Total Positions
87
Quarter
2026 Q2
Top Holding
KLAC (25.2%)
Top 10 Concentration
59.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 87
Birchview Capital, LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
KLAC
KLA CORPORATION
|
Technology | 25.18% | 16.67% |
#1
Prev: #1
|
9.0 |
—
|
158,588 | 797.6% |
P
S
|
178,471 | $53,846,485 |
$276.53
-26.3%
|
2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
BMY
BRISTOL-MYERS S...
|
Healthcare | 8.01% | 10.57% |
#2
Prev: #2
|
5.2 |
—
|
-9,025 | -2.9% |
P
S
|
297,243 | $17,127,142 | 2019 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LRCX
LAM RESEARCH CO...
|
Technology | 7.09% | 4.38% |
#3
1
Prev: #4
|
4.3 |
—
|
-1,000 | -2.8% |
P
S
|
35,000 | $15,166,550 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NTLA
INTELLIA THERAP...
|
Healthcare | 3.17% | 3.25% |
#4
3
Prev: #7
|
2.3 |
—
|
-59,500 | -13.4% |
P
S
|
385,900 | $6,780,968 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SLDB
SOLID BIOSCIENC...
|
Healthcare | 3.11% | 2.57% |
#5
4
Prev: #9
|
3.7 |
—
|
40,216 | 6.4% |
P
S
|
666,196 | $6,655,298 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BDSX
BIODESIX INC
|
Healthcare | 3.02% | 2.37% |
#6
5
Prev: #11
|
2.2 |
—
|
no change | no change |
P
S
|
286,804 | $6,467,429 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
STOK
STOKE THERAPEUT...
|
Healthcare | 2.73% | 3.89% |
#7
2
Prev: #5
|
1.6 |
—
|
-31,890 | -15.2% |
P
S
|
178,110 | $5,827,759 | 2020 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
OVV
OVINTIV INC
|
Energy | 2.65% | 3.63% |
#8
2
Prev: #6
|
2.1 |
—
|
no change | no change |
P
S
|
107,500 | $5,659,875 | 2020 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NKTR
NEKTAR THERAPEU...
|
Healthcare | 2.64% | 1.27% |
#9
10
Prev: #19
|
4.1 |
—
|
50,000 | 161.3% |
P
S
|
81,000 | $5,654,610 | 2018 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CORT
CORCEPT THERAPE...
|
Healthcare | 2.33% | 1.08% |
#10
18
Prev: #28
|
3.4 |
—
|
10,000 | 21.2% |
P
S
|
57,200 | $4,973,540 | 2015 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 2.14% | 2.04% |
#11
3
Prev: #14
|
1.9 |
—
|
no change | no change |
P
S
|
27,190 | $4,582,467 | 2015 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PRTA
PROTHENA CORP P...
|
Healthcare | 2.06% | 2.48% |
#12
2
Prev: #10
|
1.8 |
—
|
no change | no change |
P
S
|
449,019 | $4,395,896 | 2017 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ACAD
ACADIA PHARMACE...
|
Healthcare | 2.02% | 2.17% |
#13
1
Prev: #12
|
1.8 |
—
|
no change | no change |
P
S
|
171,000 | $4,326,300 | 2019 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 2.01% | 2.10% |
#14
1
Prev: #13
|
1.3 |
—
|
18 | 0.1% |
P
S
|
35,018 | $4,292,506 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CMPX
COMPASS THERAPE...
|
Healthcare | 1.72% | 4.41% |
#15
12
Prev: #3
|
2.7 |
—
|
209,133 | 14.3% |
P
S
|
1,675,000 | $3,668,250 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RLMD
RELMADA THERAPE...
|
Healthcare | 1.32% | 1.62% |
#16
Prev: #16
|
1.0 |
—
|
-1,287 | -0.3% |
P
S
|
408,100 | $2,824,052 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 1.23% | 1.01% |
#17
13
Prev: #30
|
1.5 |
—
|
no change | no change |
P
S
|
50,000 | $2,619,750 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
HALO
HALOZYME THERAP...
|
Healthcare | 1.22% | 0.37% |
#18
31
Prev: #49
|
3.5 |
—
|
23,151 | 229.2% |
P
S
|
33,251 | $2,602,556 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 1.22% | 1.27% |
#19
1
Prev: #20
|
1.0 |
—
|
-195 | -0.3% |
P
S
|
69,900 | $2,600,979 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 1.20% | 1.13% |
#20
7
Prev: #27
|
1.5 |
—
|
no change | no change |
P
S
|
30,000 | $2,555,700 | 2017 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 1.16% | 1.86% |
#21
6
Prev: #15
|
1.0 |
—
|
-20,000 | -9.1% |
P
S
|
199,000 | $2,489,490 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 1.16% | 1.01% |
#22
7
Prev: #29
|
3.0 |
—
|
13,758 | 31.3% |
P
S
|
57,758 | $2,478,396 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 1.14% | 1.52% |
#23
5
Prev: #18
|
1.0 |
—
|
6 | 0.1% |
P
S
|
4,506 | $2,441,486 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ZBIO
ZENAS BIOPHARMA...
|
Healthcare | 1.11% | 0.78% |
#24
9
Prev: #33
|
2.9 |
—
|
23,601 | 33.7% |
P
S
|
93,601 | $2,375,593 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
QURE
UNIQURE NV
|
Healthcare | 1.09% | 0.94% |
#25
7
Prev: #32
|
0.4 |
—
|
-50,000 | -49.7% |
P
S
|
50,697 | $2,335,104 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PACB
PACIFIC BIOSCIE...
|
Healthcare | 1.06% | 1.13% |
#26
Prev: #26
|
0.9 |
—
|
-150,000 | -10.0% |
P
S
|
1,350,000 | $2,268,000 | 2016 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 1.06% | — |
#27
Prev: #—
|
3.9 |
—
|
17,000 | — |
NEW
|
17,000 | $2,265,420 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VIR
VIR BIOTECHNOLO...
|
Healthcare | 1.05% | — |
#28
Prev: #—
|
3.9 |
—
|
220,000 | — |
NEW
|
220,000 | $2,241,800 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BIIB
BIOGEN INC
|
Healthcare | 0.91% | 0.52% |
#29
13
Prev: #42
|
3.4 |
—
|
4,000 | 80.0% |
P
S
|
9,000 | $1,944,540 | 2014 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
EQT
EQT CORPORATION
|
Energy | 0.86% | 1.25% |
#30
8
Prev: #22
|
1.3 |
—
|
no change | no change |
P
S
|
34,619 | $1,840,692 | 2014 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BIOA
BIOAGE LABS INC
|
Healthcare | 0.79% | — |
#31
Prev: #—
|
3.8 |
—
|
69,000 | — |
NEW
|
69,000 | $1,691,190 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TVTX
TRAVERE THERAPE...
|
Healthcare | 0.77% | 0.49% |
#32
12
Prev: #44
|
0.8 |
—
|
-200 | -0.7% |
P
S
|
29,000 | $1,647,490 | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
QDEL
QUIDELORTHO COR...
|
Healthcare | 0.73% | 0.77% |
#33
1
Prev: #34
|
2.3 |
—
|
6,829 | 8.3% |
P
S
|
89,377 | $1,565,438 | 2014 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 0.69% | 0.58% |
#34
7
Prev: #41
|
1.3 |
—
|
no change | no change |
P
S
|
6,000 | $1,468,620 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
FHTX
FOGHORN THERAPE...
|
Healthcare | 0.64% | 0.77% |
#35
Prev: #35
|
0.8 |
—
|
207 | 0.1% |
P
S
|
281,937 | $1,375,853 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BCYC
BICYCLE THERAPE...
|
Healthcare | 0.62% | 1.22% |
#36
12
Prev: #24
|
0.2 |
—
|
-149,983 | -32.4% |
P
S
|
313,616 | $1,329,732 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 0.60% | 2.74% |
#37
29
Prev: #8
|
0.2 |
—
|
-76,000 | -76.0% |
P
S
|
24,000 | $1,288,080 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 0.59% | 0.70% |
#38
1
Prev: #37
|
0.7 |
—
|
32 | 0.2% |
P
S
|
21,032 | $1,269,492 | 2022 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NVO
NOVO NORDISK A/...
|
Healthcare | 0.54% | — |
#39
Prev: #—
|
3.7 |
—
|
24,000 | — |
NEW
|
24,000 | $1,150,560 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
FCX
FREEPORT-MCMORA...
|
Basic Materials | 0.53% | 0.60% |
#40
Prev: #40
|
0.7 |
—
|
-5 | -0.0% |
P
S
|
18,035 | $1,134,198 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IMNM
IMMUNOME INC
|
Healthcare | 0.50% | 0.62% |
#41
2
Prev: #39
|
1.2 |
—
|
no change | no change |
P
S
|
50,000 | $1,059,500 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 0.48% | 0.48% |
#42
4
Prev: #46
|
1.2 |
—
|
no change | no change |
P
S
|
29,847 | $1,032,109 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
HROW
HARROW HEALTH I...
|
Healthcare | 0.48% | 0.48% |
#43
2
Prev: #45
|
1.2 |
—
|
no change | no change |
P
S
|
24,000 | $1,019,280 | 2019 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ADAG
ADAGENE INC
|
Healthcare | 0.47% | — |
#44
Prev: #—
|
3.7 |
—
|
240,000 | — |
NEW
|
240,000 | $1,008,000 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 0.44% | — |
#45
Prev: #—
|
3.7 |
—
|
20,000 | — |
NEW
|
20,000 | $940,800 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SLN
SILENCE THERAPE...
|
Healthcare | 0.37% | — |
#46
Prev: #—
|
3.6 |
—
|
71,218 | — |
NEW
|
71,218 | $781,974 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 0.30% | 0.37% |
#47
3
Prev: #50
|
0.6 |
—
|
53 | 0.6% |
P
S
|
8,741 | $651,030 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
FDMT
4D MOLECULAR TH...
|
Healthcare | 0.30% | — |
#48
Prev: #—
|
3.6 |
—
|
48,505 | — |
NEW
|
48,505 | $645,117 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 0.28% | — |
#49
Prev: #—
|
3.6 |
—
|
16,487 | — |
NEW
|
16,487 | $606,722 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 0.28% | 1.23% |
#50
27
Prev: #23
|
0.1 |
—
|
-140,000 | -71.8% |
P
S
|
55,000 | $596,750 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-50 of 87 holdings